Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma
…estimated 99,780 new cases diagnosed and 7,650 deaths due to melanoma in 2022. A steep drop in melanoma deaths from…
Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma
…estimated 99,780 new cases diagnosed and 7,650 deaths due to melanoma in 2022. A steep drop in melanoma deaths from…
,
Navigating the Journey Together – Conversations with Melanoma Caregivers
…has received, contributing positively to the lives of others on their melanoma journeys. Nancy Earle: Nancy devoted herself as a…
,
News from ESMO: NADINA Trial Update in Stage III Melanoma
…melanoma.3 Prior to NADINA, medical intervention started with surgery, and was followed with drug therapy for most types of cancer,…
,
Oncolytic Virotherapy Shows Promise in Advanced Melanoma that Failed Immunotherapy
New clinical trial data shows that additional options may soon become available for patients with melanoma for whom immunotherapy did…
,
Navigating Melanoma Together: 2024 Podcast Wrap-Up
…resource for information, support, and connection. We look forward to continuing to provide the insights and resources you need on…
,
,
New Therapy in Clinical Trial Returns Immunotherapeutic Activity to Resistant Melanoma
…because specific mechanisms develop within melanoma cells that cause resistance. Among the ways melanoma cells work to survive and evade…
,
SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma
First and only prospective blinded data confirm the Merlin CP-GEP (Clinicopathological-Gene Expression Profiling) Test accurately stratifies melanoma patients by sentinel…
,
,
KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma
…melanoma patients.” “These long-term overall survival results further solidify KIMMTRAK as the first-line standard of care for HLA-A*02:01 positive patients…
,
,
WIM: Emphasizing the Whole Patient and the Whole Physician
By, Vallerie A. Malkin In August of 2017, AIM at Melanoma hosted the inaugural Women in Melanoma Initiative in…
,
Survivor Profile: Karlee Steele, Stage IIIB Survivor
…melanoma, and per her doctor, it originated from her second melanoma, the one on her shoulder. Yes, that tumor on…
,
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026